Background

48
Timely and complete reporting of the results of clinical trials is an ethical imperative [1] ; it helps to 49 eliminate duplicative effort, enables researchers to develop more up-to-date study hypotheses and 50 allows clinicians and patients to judge the benefits or risks of different therapies. Although the 51 pharmaceutical industry has made great strides to address criticism for a perceived lack of 52 transparency in the disclosure of clinical trial results, the quality, ethics and timeliness of clinical trial 53 reporting remain closely scrutinized for both industry-funded and academically funded trials [2] [3] [4] [5] [6] . 54
Pharmaceutical companies often offer authors professional medical writing support (PMWS) to assist 55 in the reporting of clinical trial results [7] . International guidelines endorse the acknowledgement of 56 PMWS [8, 9] , and the proportion of articles in the medical literature with such an acknowledgement is 57 6-19% [7, 10, 11] . We conducted a systematic review to identify and analyse published studies that 58 investigated the association between PMWS and the quality, ethics and timeliness of clinical trial 59 reporting. 60
Methods
61
Systematic literature search 62
Published studies relating to medical writing were identified through a systematic literature review. 'medical writ*' and 'medical publication professional'. Supplementary searches were limited to 75 2014-2017. We contacted the corresponding authors of congress abstracts identified in the 76 supplementary searches to request access to full posters/presentations. The bibliographies of studies 77 identified in the electronic searches were also reviewed to identify additional relevant references. 78
Study selection and data collection 79
All identified studies were screened against inclusion and exclusion criteria in accordance with the 80 2009 Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines 81 [12] . For congress abstracts identified in the supplementary searches, full posters were obtained from 82 the ISMPP website or from the authors. Identified congress abstracts were excluded as 'duplicates' if 83 a full version of the study had been published. Studies eligible for inclusion were in English, and 84 compared the quality, ethics or timeliness of articles reporting clinical trials that had been developed 85 with and without acknowledged PMWS. Studies that did not directly compare clinical trial 86 publications that had been developed with and without PMWS were excluded, as were those that 87 reported outcomes that were unrelated to quality, ethics or timeliness, and those that assessed study 88 types other than clinical trials. 
Results
96
Search results 97
Our searches identified 75 potentially relevant publications after exclusion of 22 duplicate 98 publications; 70 were excluded during screening and full paper review, and three were identified in 99 bibliographies of identified studies (Figure 1 ). Of the eight included studies, three were full 100 publications (two in peer-reviewed journals [13, 14] , one in a non-peer reviewed journal [15] ), and 101 five were congress abstracts (four poster presentations [16] [17] [18] [19] , one oral presentation [20] ). Although 102 no date limit was included in the search strategy, only two of the identified studies were published 103 before 2015: one in 2006 [7] and the other in 2010 [15] ( Table 1) . The eight included studies analysed 104 849 articles that had been developed with PMWS and 2073 articles developed without. 105
Quality of reporting 106
Of the identified studies comparing articles developed with and without PMWS, three assessed 107 adherence to CONSORT guidelines [14, 15, 19] . Each of these studies, using a different statistical 108 approach to assess adherence, showed that PMWS was associated with increased adherence to 109 CONSORT guidelines ( Table 2 ). Articles developed with PMWS were significantly more likely to 110 report completely at least 50% of the assessed CONSORT items (p < 0.05) [14, 21] and to comply 111 with more CONSORT items than articles without PMWS (p < 0.05) [15] . Similarly, articles with 80-112 100% compliance with CONSORT items were significantly more likely to have been developed with 113 PMWS than those with less than 80% compliance (p < 0.0001) [19] . Looking at individual 114 CONSORT items, one identified study showed that articles with PMWS were significantly more 115 likely to report all important adverse events or side effects than those without PMWS [15] , and 116 another showed that PMWS increased adherence to six of 12 CONSORT items assessed: specification 117 of primary outcome; sample size calculation; type of randomization; publication of a participant flow 118 diagram; provision of dates defining recruitment and follow-up; and details of trial registration [14] . 119
Additionally, in this study, another CONSORT item (who generated the allocation sequence) was 120 Evuarherhe et al. PMWS systematic review 6 only reported in 5/110 articles developed with PMWS and none of the 123 articles without PMWS; 121 thus, a relative risk could not be calculated [14] . One additional study assessed adherence to 122 CONSORT-A and showed that PMWS was not associated with an overall increase in adherence [13] ; 123 PMWS was associated with lower levels of adherence with respect to reporting of study setting and 124 higher levels of adherence in relation to disclosure of harms/side effects and funding source in the 125 abstract [13] . 126
Two studies which represented different analyses of the same group of articles looked at other 127 markers of quality in reporting (Table 2) [14, 17] . In these studies, PMWS was positively associated 128 with various measures of reporting quality, including a higher standard of written English (p < 0.01) 129 [14, 21] , higher likelihood of publication in a journal with an impact factor (p = 0.001) [17] , and 130 higher mean impact factor of the journal accepting the article (p < 0.001) [17] . However, there was no 131 association between PMWS and article-level measures of impact, such as mean number of citations 132 per year (p = 0.11), mean number of article views per year (p = 0.84) and Altmetric score (p = 0.55) 133 (Table 2 ) [17] . 134
Ethics of publication 135
Of the identified studies, one examined the relationship between outcome reporting and PMWS using 136 data from the publicly available Centre for Evidence-Based Medicine Outcome Monitoring Project 137 (COMPare) [22] . PMWS was associated with the reporting of fewer non-pre-specified outcomes 138 (p = 0.028) [16] . 139
Timeliness of publication 140
Three studies looked at the timeliness of clinical trial reporting in articles developed with or without 141 PMWS (Table 2) [14, 18, 20] . The only study investigating the complete manuscript development time, 142 from last patient visit in clinical trials to article publication, showed that PMWS was associated with 143 reduced time to publication [18] . Two studies investigating the timing of one step in the process, from 144 manuscript submission to acceptance, showed inconsistent results [14, 20] . In the first of these studies, 145 PMWS was associated with increased time from manuscript submission to acceptance, although the 146 Evuarherhe et al. PMWS systematic review 7 mean number of versions submitted was unchanged [14] ; in the second study, time from manuscript 147 submission to acceptance was reduced, but not significantly [20] . 148 English), ethics (reporting of non-pre-specified outcomes) and timeliness (time to publication). The 155 improvement in CONSORT adherence associated with PMWS is perhaps unsurprising, given that 156 professional medical writers are routinely trained in Good Publication Practice (GPP3) for the 157 development of peer-reviewed manuscripts [23] ; GPP3 guidelines state that authors should follow 158 established reporting standards, including CONSORT [8, 9] . Although PMWS was associated with 159 improved adherence to CONSORT, it was not associated with improved adherence to CONSORT-A, 160
Conclusions
suggesting that although professional medical writers improve disclosure overall, they may need to 161 prioritize improving the reporting in the abstract (which is all that is read by many readers). 162
The improvements in manuscript quality may not be reflected by increased article impact and social 163 media attention. In the one study identified in our systematic review, which examined measures of 164 article impact, there were no significant differences between articles developed with and without 165 PMWS in relation to Altmetric score, number of citations per year and number of article views per 166
year. Medical publications professions have no influence on the subject matter or relevance of the 167 clinical trial and, as such, PMWS may not be expected to affect an article's post-publication impact. 168
It is important that authors remain transparent about which specific clinical trial outcomes will be 169 measured and reported. The COMPare project determined the proportion of pre-specified and non-170 pre-specified outcomes that were reported in clinical studies published in the top five medical journals 171 over a 3-month period [22] . In the present systematic review, one included study conducted a sub-172 Evuarherhe et al. PMWS systematic review 8 analysis of the publicly available COMPare data and assessed the relationship between PMWS and 173 outcome reporting. The authors found that fewer non-pre-specified outcomes were reported for 174 articles developed with PMWS than for those developed without. This is not the only study to have 175 shown a positive association between PMWS and publication ethics. For instance, a recent study 176 showed that PMWS is associated with increased transparency relating to the source of funding, the 177 author disclosures of financial interest and the acknowledgements of conflicts of interest (or lack 178 thereof) in health economics and outcomes research publications [24] ; another study showed that, of 179 214 publications retracted owing to misconduct between January 1966 and February 2008, only three 180 declared PMWS [25] . 181
One included study looking at the influence of PMWS on timeliness found that PMWS was associated 182 with reduced time from last patient visit to article publication. This period includes processes in which 183 professional medical writers are involved and have a major role, namely manuscript preparation, 184 editing and submission. Two other included studies that examined the influence of PMWS on time 185 from manuscript submission to acceptance revealed mixed results. One of the studies found that time 186
to acceptance was reduced with PMWS, but that the difference was not statistically significant. The 187 other study found that time to acceptance was increased with PMWS; however, it should be noted that 188 the period from submission to article acceptance is not primarily the responsibility of professional 189 medical writers. 190
Clinicians have reported lack of time as a common reason for non-publication of research findings 191 [26] [27] [28] . By specializing in preparation of clinical trial publications, professional medical writers are 192 well placed to aid in the rapid dissemination of trial findings under the direction of the authors, 193 subject to strict publication guidelines [9] . In fact, results from a recent survey showed that authors 194 who use PMWS were more likely to have published as first author at least once in the previous 2 195 years [29] , suggesting that PMWS can also improve overall publication rates. 196
This systematic review has some limitations, notably that study inclusion was largely based on the 197 assumption that differences in outcomes were attributable to PMWS. It is possible that other factors 198 Evuarherhe et al. PMWS systematic review 9 caused these differences in quality and timeliness. This issue may affect the results of individual 199 studies, but this systematic review combined results from different studies looking at different 200 outcomes of interest, and showed a consistent benefit of PMWS on manuscript quality (including 201 adherence to publication guidelines, quality of written English and publication in high-quality 202 journals), ethics (reporting of pre-specified outcomes) and timeliness (time from completion of trial to 203 publication). Taken together, the findings of this systematic review support the conclusion that 204 PMWS has a positive impact on the high-quality, ethical and timely dissemination of clinical trial 205 data. 206
The included studies classified articles as having been developed with PMWS only when there was a 207 clear acknowledgement of this support. As such, it is possible that some of the studies classified as 208 having been developed with no PMWS might have had PMWS but had simply failed to acknowledge 209 it. By classifying publications with no clear acknowledgment of PMWS as 'without PMWS', the 210 studies identified in this systematic review may have underestimated the effects of PMWS. To 211 minimize the risk of publication bias we employed a broad search strategy with no limits on date, 212 country, language or type of observational study. Most of the identified studies were sourced from 213 conference proceedings (for which the full poster or oral presentation was available in 4/5 cases) and 214 one was published in a non-peer-reviewed journal. 215
In the identified studies, the outcome measures chosen were widely accepted as measures of quality 216 and completeness. For instance, CONSORT is an independently developed measure of reporting 217 standards recommended by the International Committee of Medical Journal Editors and also medical 218 publications and medical writing societies, including ISMPP, EMWA and the American Medical 219 Writers Association [9] . Other outcomes of interest assessed in this review were assigned 220 independently of the investigators involved in each of the articles analysed in each included study 221 (e.g. standard of written Englishassessed during peer review of analysed articles [17] ). As such, in 222 this systematic review, we have been successful in analysing a range of outcomes assessed in 223 observational ('real-world') studies in a standardized manner that minimizes publication bias. 224
Further research is needed to elucidate the role of PMWS in clinical trial publication, particularly with 225 regard to productivity and added value [30] . Further research is also required to assess the impact of 226 PMWS in other types of studies published by the pharmaceutical industry, such as observational 227 studies and systematic reviews. As our systematic review identified that most studies of PMWS have 228 only been presented at conferences or published in non-peer-reviewed journals, it is crucial that future 229 studies are published in full in peer-reviewed journals. [31] 230
Currently, the pharmaceutical industry is more likely than non-industry institutions to disclose clinical 231 trial results properly [32] . This is probably due to a larger investment in internal processes and 232 infrastructure, which includes the use of professional medical writing support. In fact, there have been 233 calls for professional medical writers and publication experts to be employed by academic institutions 234 [33, 34] . Additionally, in a survey looking at attitudes to PMWS, academic and clinician respondents 235 to an online survey were generally accepting of PMWS, particularly its influence on editing, journal 236 styling and adherence to reporting guidelines, with 84% of respondents stating that they valued 237 PMWS [35] . In this survey, 82.9% of respondents felt that it was acceptable to receive PMWS; in 238 another survey, PMWS was seen as 'adding value to publication development' by almost 90% of 239 participants [35] . Our systematic review appraising current research in this area helps to substantiate 240 the positive attitude to PMWS that is held by clinical and academic professionals seeking to ensure 241 the ethical, accurate and timely publication of clinical trials. Reviews and Meta-Analyses; RCT, randomized controlled trial; RR, relative risk; SD, standard 249 deviation. 250
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